Article
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
International journal of oncology - 1 Sept 2016
Caporali Simona, Alvino Ester, Lacal Pedro Miguel, Levati Lauretta, Giurato Giorgio, Memoli Domenico, Caprini Elisabetta, Antonini Cappellini Gian Carlo, D'Atri Stefania
Abstract excerpt
BRAF inhibitors (BRAFi) have proven clinical benefits in patients with BRAF-mutant melanoma. However, acquired resistance eventually arises. The effects of BRAFi on melanoma cell proliferation and survival have been extensively studied, and several mechanisms involved in acquired resistance to the growth suppressive activity of these drugs have been identified. Much less is known about the impact of BRAFi, and in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.